PMID- 14687621
OWN - NLM
STAT- MEDLINE
DCOM- 20040322
LR  - 20220330
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 28
IP  - 3
DP  - 2004 Mar
TI  - Interleukin-18 in multiple myeloma patients: serum levels in relation to response 
      to treatment and survival.
PG  - 259-66
AB  - Interleukin-18 (IL-18) plays a role in the host's response to tumours and 
      angiogenesis. We determined serum levels of IL-18, vascular endothelial growth 
      factor (VEGF), angiogenin (ANG), tumor necrosis factor (TNF-alpha) and CRP in 65 
      newly diagnosed myeloma patients. IL-18, VEGF, angiogenin, TNF-alpha and CRP were 
      significantly higher at stage III in comparison to stages II and I. These 
      cytokines (measured in 27 patients) significantly decreased after treatment. In 
      survival analysis, higher levels of IL-18 were associated with a poorer 
      prognosis. We conclude that increased serum IL-18 in myeloma patients correlates 
      with advanced disease, increased levels of angiogenic cytokines and worse 
      survival.
FAU - Alexandrakis, M G
AU  - Alexandrakis MG
AD  - Division of Medicine, University Hospital of Heraklion, Medical School of Crete, 
      PO Box 1352, Crete, Greece. freda@med.uoc.gr
FAU - Passam, F H
AU  - Passam FH
FAU - Sfiridaki, K
AU  - Sfiridaki K
FAU - Moschandrea, J
AU  - Moschandrea J
FAU - Pappa, C
AU  - Pappa C
FAU - Liapi, D
AU  - Liapi D
FAU - Petreli, E
AU  - Petreli E
FAU - Roussou, P
AU  - Roussou P
FAU - Kyriakou, D S
AU  - Kyriakou DS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Interleukin-18)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 5J49Q6B70F (Vincristine)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 80168379AG (Doxorubicin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.1.27.- (angiogenin)
RN  - EC 3.1.27.5 (Ribonuclease, Pancreatic)
RN  - Q41OR9510P (Melphalan)
RN  - VB0R961HZT (Prednisone)
RN  - AP protocol 2
RN  - VAD protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/therapeutic use
MH  - C-Reactive Protein/analysis
MH  - Dexamethasone/administration & dosage
MH  - Disease Progression
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Interleukin-18/*blood
MH  - Life Tables
MH  - Male
MH  - Melphalan/administration & dosage
MH  - Middle Aged
MH  - Multiple Myeloma/*blood/drug therapy/mortality
MH  - Neoplasm Proteins/*blood
MH  - Prednisone/administration & dosage
MH  - Prospective Studies
MH  - Ribonuclease, Pancreatic/blood
MH  - Survival Analysis
MH  - Tumor Necrosis Factor-alpha/analysis
MH  - Vascular Endothelial Growth Factor A/blood
MH  - Vincristine/administration & dosage
EDAT- 2003/12/23 05:00
MHDA- 2004/03/23 05:00
CRDT- 2003/12/23 05:00
PHST- 2003/12/23 05:00 [pubmed]
PHST- 2004/03/23 05:00 [medline]
PHST- 2003/12/23 05:00 [entrez]
AID - S0145212603002613 [pii]
AID - 10.1016/s0145-2126(03)00261-3 [doi]
PST - ppublish
SO  - Leuk Res. 2004 Mar;28(3):259-66. doi: 10.1016/s0145-2126(03)00261-3.